Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: Experience from KIGS (Pfizer international growth database)

Hormone Research

Volumn 70, Issue 3, 2008, Pages 182-187

  Lindgren, A C ^a   Lindberg, A ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Pfizer Medical Outcomes   (Sweden)

Author keywords

Body composition; Growth hormone; Near adult height; Prader Willi syndrome

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE;

ADOLESCENT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY HEIGHT; BODY WEIGHT; CALORIC INTAKE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG EFFECT; FEMALE; GLUCOSE INTOLERANCE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LEAN BODY WEIGHT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PUBERTY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ABSORPTIOMETRY, PHOTON; BODY COMPOSITION; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; LONGITUDINAL STUDIES; MALE; PRADER-WILLI SYNDROME;

EID: 47949102974     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000145019     Document Type: Article

References (26)

1. Burman P, Ritzén EM, Lindgren AC: Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 2001;22:787-799.
2. Nicholls RD, Ohta T, Gray TA: Genetic abnormalities in Prader-Willi syndrome and lessons from mouse models. Acta Paediatr Suppl 1999;88:99-104.
3. Swaab D, Purba J, Hofman M: Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome. J Clin Endocrinol Metab 1995;80:573-579.
4. Swaab D: Prader-Willi syndrome and the hypothalamus. Acta Paediatr Suppl 1997;423:50-54.
5. Brambilla P, Bosio L, Manzoni P, Pietrobelli A, Beccaria L, Chiumello G: Peculiar body composition in patients with Prader-Labhart-Willi syndrome. Am J Clin Nutr 1997;65:1369-1374.
6. Lindgren AC: Somatropin therapy for children with Prader-Willi syndrome: guidelines for use. Treat Endocrinol 2006;5:223-228.
7. Myers SE, Carrel AL, Whitman BY, Allen DB: Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr 2000;137:42-49.
8. Carrel AL, Myers SE, Whitman BY, Allen DB: Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab 2002;87:1581-1585.
9. Eiholzer U, l'Allemand D: Growth hormone normalizes height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy. Horm Res 2000;53:185-192.
10. Lindgren AC, Hagenäs L, Müller J, Blichfeldt S, Rosenborg M, Brismar T, Ritzén EM: Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably. Acta Paediatr 1998;87:28-31.
11. Karlberg P, Taranger J: The somatic development of children in a Swedish urban community. Acta Paediatr Scand Suppl 1976;258:1-148.
12. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA: Cross-sectional stature and weight reference curves for the UK 1990. Arch Dis Child 1995;73:17-24.
13. Cole TJ, Freeman JV, Preece MA: Body mass index reference curves for the UK, 1990. Arch Dis Child 1995;73:25-29.
14. Hauffa BP, Schlippe G, Roos M, Gillessen-Kaesbach G, Gasser T: Spontaneous growth in German children and adolescents with genetically confirmed Prader-Willi syndrome. Acta Paediatr 2000;89:1302-1311.
15. van der Sluis IM, de Ridder MA, Boot AM, Krenning EP, de Muinck Keizer-Schrama SM: Reference data for bone density and body composition measured with dual-energy X-ray absorptiometry in white children and young adults. Arch Dis Child 2002;87:341-347.
16. Tothill P, Avenell A, Love J, Reid DM: Comparisons between Hologic, Lunar and Norland dual-energy X-ray absorptiometers and other techniques used for whole-body soft tissue measurements. Eur J Clin Nutr 1994;48:781-794.
17. Luthman M, Jónsdóttir I, Skoog B, Wivall IL, Roos P, Werner S: Monoclonal antibodies reveal circulating growth hormone of high molecular weight not detectable by conventional assays. Acta Endocrinol (Copenh) 1990;123:317-323.
18. Bang P, Eriksson U, Sara V, Wivall I-L, Hall K: Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 1991;124:620-629.
19. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jørgensen K, Müller J, Hall K, Skakkebæk NE: Serum insulin-like growth factor-I in 1030 healthy children, adolescents and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994;78:744-752.
20. Wollmann HA, Schultz U, Grauer ML, Ranke MB: Reference values for height and weight in Prader-Willi syndrome based on 315 patients. Eur J Pediatr 1998;157:634-642.
21. Eiholzer U, Gisin R, Weinmann C, Kriemler S, Steinert H, Torresani T, Zachmann M, Prader A: Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance. Eur J Pediatr 1998;157:368-377.
22. Mauras N, Rogol AD, Haymond MW, Veldhuis JD: Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty. Horm Res 1996;45:74-80.
23. van Coeverden SC, Netelenbos JC, de Ridder CM, Roos JC, Popp-Snijders C, Delemarrevan der Waal HA: Bone metabolism markers and bone mass in healthy pubertal boys and girls. Clin Endocrinol (Oxf) 2002;57:107-116.
24. Lindgren AC, Hagenas L, Ritzen EM: Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin hemostasis. Swedish National Growth Hormone Advisory Group. Horm Res 1999;51:157-161.
25. Eiholzer U, Stutz K, Weinmann C, Torresani T, Molinari L, Prader A: Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. Eur J Pediatr 1998;157:890-893.
26. Holm VA, Laurnen EL: Prader-Willi syndrome and scoliosis. Dev Med Child Neurol 1981;23:192-201.